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Abstract
Characterizing interactions between drugs is important to avoid potentially harmful combinations, to reduce off-target
effects of treatments and to fight antibiotic resistant pathogens, among others. Here we present a network inference
algorithm to predict uncharacterized drug-drug interactions. Our algorithm takes, as its only input, sets of previously
reported interactions, and does not require any pharmacological or biochemical information about the drugs, their targets
or their mechanisms of action. Because the models we use are abstract, our approach can deal with adverse interactions,
synergistic/antagonistic/suppressing interactions, or any other type of drug interaction. We show that our method is able to
accurately predict interactions, both in exhaustive pairwise interaction data between small sets of drugs, and in large-scale
databases. We also demonstrate that our algorithm can be used efficiently to discover interactions of new drugs as part of
the drug discovery process.
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Introduction
Understanding interactions between drugs is becoming increas-
ingly important. A recent large-scale study of older adults (ages
57–85) in the U.S. found that 29% of them use five or more
prescription medications concurrently, and that as many as 4%
may be at risk of having a major adverse drug-drug interaction [1].
For this reason, the evaluation of drug interactions is ‘‘an integral
part of drug development and regulatory review prior to its market
approval’’ [2], and institutions like the FDA put much effort in
developing guidelines for in vitro and in vivo studies, as well as for
developing in silico models and methods.
Potentially beneficial effects of drug interactions, on the other
hand, are equally important. Indeed, some drugs show synergistic
effects against their targets, which not only increases the efficacy of
treatments but may also improve the selectivity and reduce off-
target effects [3]. Antagonistic interactions can be used to study the
mechanisms of action of drugs [4], and even suppressing
interactions between drugs, in which one drug inhibits the action
of the other, have been found to be potentially very relevant in the
fight against antibiotic-resistant pathogens [5].
More broadly, it is becoming increasingly clear that drug
interactions leading to network effects at a systems level are the norm
in pharmacology, rather than the exception [6–11]. According to
some, these network effects may even be at the root of the dismal results
of attempts to develop single-target drugs, and of the simultaneous
decline of drug development productivity [7]. Therefore, network
pharmacology is emerging as a new paradigm in drug discovery.
However, despite the conceptual appeal of abstract network
approaches to drug development, one may argue that the
contributions of network analysis have so far been relatively
modest. Indeed, most of these contributions have been related to
pointing out network properties that make certain proteins more
likely to be good targets [8], for example connector versus non-
connector enzymes [12,13], or central versus peripheral proteins
[11]. These contributions notwithstanding, there is little in the
form of actual, concrete, examples where network analysis has
resulted in a clear application to the discovery of new drugs or to
the study of the effects of existing drugs.
Here we present one such application. In particular, we use the
information that is encoded in networks of reported drug
interactions to predict uncharacterized interactions. Because the
models we use are abstract, our approach can deal with adverse
interactions as well as synergistic/antagonistic/suppressing inter-
actions or any other type of drug interaction. We show that our
method is able to accurately predict drug interactions, and that it
can be used efficiently to discover interactions of new drugs as part
of the drug discovery process.
Results
A network approach for the inference of unknown drug
interactions
For specific drug pairs, interactions can be predicted in silico
from mechanistic or flux balance models of the pathways and
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processes in which their targets are involved [6,14]. However, this
approach is difficult to generalize and is, therefore, inappropriate
for large-scale identification of interactions and for the identifica-
tion of interactions between drugs whose mechanisms are not fully
understood. Another approach is to use statistical models based on
molecular and pharmacological data [15] but, again, such data is
not always available. Finally, there are mechanism-independent
methods to predict multidrug interactions based on maximum
entropy approaches, but these require knowledge of pair
interactions [16], which is what we aim to uncover here.
As in other biological problems, network theory [11,17,18]
provides a useful, although abstract, alternative to mechanistic and
molecular modeling. In a network representation of drug
interactions, each node represents a drug and each link represents
an interaction between the corresponding pair of drugs. Interac-
tions of different types (for example, synergistic versus antagonistic)
are represented by links of different types (Fig. 1A).
Drug interaction networks contain explicit information about
the interactions that are known, but also about implicit
information about interactions that have never been tested; the
question we are concerned with is how to extract this information
from the network. Here, we present a network-based approach to
predict an interaction rij between drugs i and j from a network N
O
of known drug interactions (which includes i and j but no explicit
information about their interaction rij ). Our approach deals
rigorously with the information contained in the network by
means of Bayesian model averaging [19] (Methods). The approach
is completely unsupervised and parameter-free.
Within our Bayesian model averaging approach, the only
relevant modeling question is what family of models can accurately
describe the network of drug interactions. In this regard, it is well
established that pairwise drug interactions are largely determined
by the cellular functions targeted by the drugs [20–22]. In network
terms, this means that the interaction rij is determined by the
cellular functions si and sj of i and j, respectively; in other words,
nodes can be partitioned into groups (by cellular function) such
that the interaction between any pair of nodes depends only on the
groups to which they belong (Fig. 1B–C). Stochastic block models
are a family of network models that mathematically formalize the
idea of group-dependent interactions [23–25]. Although originally
proposed in the context of social interactions, stochastic block
models are increasingly used to describe the structure of complex
networks in general [19,26] and for network inference [19]
(Methods). Again, after this choice of plausible models the
resulting algorithm is completely unsupervised and parameter-
free (Methods).
To benchmark the performance of our algorithm, we consider
two alternative heuristic approaches. The first benchmark is based
on the idea that similar drugs have similar interactions. In this
spirit, we set rij~ri’j’, where i’ (respectively, j’) is a drug whose
known interactions are as similar as possible to those of i (j), and
ri’j’ is a known interaction (Methods). Second, we consider an
approach based on the Prism algorithm, which was developed to
identify groups of drugs (or genes) with similar interactions to other
drugs [20,27]. Instead of averaging over all possible partitions of
drugs into groups as done in our Bayesian model averaging
approach, we take the partition proposed by Prism and use that
partition to make the prediction (Methods).
Additionally, we consider as a baseline the simplest possible
algorithm for predicting rij , which is to use the overall rate of each
interaction type in the network. For example, if 60% of known
interactions in a network are synergistic (S) and 40% are
antagonistic (A), then we set rij~S with 60% probability and
rij~A with 40% probability. This baseline captures the fact that it
is harder to make a prediction when the ratio of S=A interactions
is 60/40 than when the ratio is, for example, 95/5.
Figure 1. Stochastic block models for the prediction of
unknown drug interactions. (A) Consider a hypothetical situation
in which all of the interactions between drugs A{H are known with
the exception of the interaction between B and G, which is, in reality,
antagonistic. There are many partitions of the drugs into groups. The
partition in (B) has high explanatory power (low value of H(P) in Eqs.
(5) and (6)), since most drug interactions between a pair of groups are
of the same type. Therefore, the predictions of this partition have a
large contribution to the estimation of the probability of the
unknown interaction. Conversely, the partition depicted in (C) has
little explanatory power (high value of H(P)) and has a small
contribution to the estimation of the probability of the unknown
interaction.
doi:10.1371/journal.pcbi.1003374.g001
Author Summary
Over one in four adults older than 57 in the US take five or
more prescriptions at the same time; as many as 4% are at
risk of a major adverse drug-drug interaction. Potentially
beneficial effects of drug combinations, on the other hand,
are also important. For example, combinations of drugs
with synergistic effects increase the efficacy of treatments
and reduce side effects; and suppressing interactions
between drugs, in which one drug inhibits the action of
the other, have been found to be effective in the fight
against antibiotic-resistant pathogens. With thousands of
drugs in the market, and hundreds or thousands being
tested and developed, it is clear that we cannot rely only
on experimental assays, or even mechanistic pharmaco-
logical models, to uncover new interactions. Here we
present an algorithm that is able to predict such
interactions. Our algorithm is parameter-free, unsuper-
vised, and takes, as its only input, sets of previously
reported interactions. We show that our method is able to
accurately predict interactions, even in large-scale data-
bases containing thousands of drugs, and that it can be
used efficiently to discover interactions of new drugs as
part of the drug discovery process.
Network Inference for Drug-Drug Interactions
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Validation on exhaustive pairwise interaction data
We start by testing the algorithms described above against two
experiments in which all pairwise interactions between a small set
of drugs were exhaustively tested [20,28]. In the first experiment,
Yeh and coworkers tested the effect of all pairwise combinations of
21 antibiotics on E. coli’s growth [20]. They classified each
interaction as synergistic, additive, antagonistic or suppressing. In
the second experiment, Cokol and coworkers studied the effect of
all pairwise combinations of 13 anti-fungal drugs on the growth of
S. cerevisiae [28]. They classified interactions as synergistic, additive
or antagonistic (except for some interactions that were unresolved).
To study the performance of the algorithms, we simulate
situations in which not all pairwise interactions are known. In
particular, we simulate a situation in which only a fraction of all
interactions are observed, and then try to predict the unobserved
interactions (repeated random sub-sampling validation). In each
case, we measure the fraction of predictions that are exactly
correct (exact classification), as well as the fraction of predictions
that deviate from the experimental observation by at most one level
(+1 classification). For example, miss-predicting a synergistic
interaction as additive is considered correct by the +1 classifica-
tion metric, but miss-predicting a synergistic as antagonistic or
suppressing (or vice versa), or an additive as suppressing (or vice
versa) is considered incorrect.
In Fig. 2 we show the results of the validation. As expected, the
stochastic block model, the neighbor-based and the Prism-baed
predictions have accuracies well above the baseline, even when as
many as 80% of the interactions are unobserved. In the majority of
cases, the stochastic block model is significantly and consistently
more accurate than the neighbor-based and the Prism-based
predictions with one exception: when the fraction of observed
interactions is high (§70%) in the Cokol dataset, in which the
neighbor-based prediction is best. Note that as soon as the number
of interaction types grows (from 3 in Cokol to 4 in Yeh) or the
fraction of observed interactions decreases, the stochastic block
model becomes more accurate. Moreover, even when the
neighbor-based exact predictions are more accurate, 61 predic-
tions are always more accurate for the stochastic block model.
Although the absolute differences of prediction accuracy
between the stochastic block model and the neighbor-based
approach may seem modest (typically, between 5 and 10 percent
points), it is important to note that relative to the baseline the
improvements are quite major (Fig. 2E–F). Indeed, when the
fraction of observed interactions is 50%, the stochastic block
model represents a 29% and a 63% improvement (for the Cokol
and Yeh datasets, respectively) in exact classifications over the
neighbor-based approach, and a 55% and 66% over the Prism-
based approach (always, with respect to the baseline). When we
only observe 20% of the interactions, the relative improvements
are 126% and 133% over neighbor-based predictions, and 61%
and 154% over Prism-based predictions.
Validation on evolving databases of drug interactions
Next, we test our algorithm against the existence of adverse
drug interactions in two drug interaction databases: the database
available through the web site Drugs.com and the DrugBank
database [29,30]. For the Drugs.com database, we restrict our
analysis to major adverse interactions between generic drugs; for
the DrugBank, we consider all interactions.
We consider two snapshots of each of the databases. For the
Drugs.com database, we collected the first snapshot in May 10,
2010, and the second one in February 22, 2012. A total of 1,518
drugs are listed in both snapshots. There are 32,074 drug
interactions present in both instances of the network; nN~1,349
novel interactions present in the 2012 dataset but not in the 2010
dataset, and nS~165 spurious interactions present in the 2010
dataset but not present in the 2012 dataset. For the DrugBank
dataset, the first snapshot corresponds to January 2009, and the
second to April 2012. A total of 1,012 drugs are listed in both
snapshots; there are 9,113 drug interactions present in both
instances of the network, with nN~1,190 and nS~233.
We evaluate to what extent could our network algorithms have
predicted which interactions needed to be added to each of the
first snapshots (that is, to what extent can the algorithms uncover
novel interactions), and which ones needed to be removed (that is,
to what extent can they detect spurious interactions). As we show
in Fig. 3, the algorithm based on stochastic block models is able to
accurately uncover spurious and, especially, novel interactions. In
contrast, neighbor-based and Prism-based predictions perform
only marginally better than the baseline.
First, we measure the area under the receiver operating
characteristic (AUROC) curve (Fig. 3A–B) [31]. In the case of
uncovering novel interactions, the AUROC gives the probability
that an interaction randomly chosen from those that were added
to the first snapshot has a higher score than one randomly chosen
from the set of interactions that were never added to the network.
For the Drugs.com database, we find this probability to be 0.87 for
the stochastic block model, 0.53 for neighbor-based predictions,
and 0.52 for Prism-based predictions. For the DrugBank dataset,
these probabilities are 0.71, 0.52 and 0.53, respectively.
Similarly, when dealing with spurious interactions, the AUROC
gives the probability that an interaction randomly chosen from
those that were removed from the 2010 snapshot has a lower score
than one randomly chosen from the set of interactions that were
not removed from the network. For the Drugs.com database, we
find this probability to be 0.73 for the stochastic block model, 0.51
for neighbor-based predictions, and 0.45 for Prism-based predic-
tions. For the DrugBank dataset, these probabilities are 0.61, 0.50
and 0.50, respectively.
It is also interesting to analyze the sensitivity-specificity curves
(Fig. 3C–F). Consider first the results for the Drugs.com database.
For the most pressing case of uncovering previously unreported
major drug interactions (Fig. 3C), we find that at 95% sensitivity,
the stochastic block model has a specificity of 62%, that is, that we
could have built, in 2010, a list of potential interactions containing
95% of the interactions that were actually added to the database,
and excluding 62% of those that were never added. Conversely, at
95% specificity we obtain a sensitivity of 45%, that is, a list
containing only 5% of the interactions that were never added to
the network would have included close to half of all the
interactions that were actually added to the database. While
results for spurious interactions and for the DrugBank dataset are
more modest, our method, unlike the neighbor-based or the
Prism-based algorithms, has significant predictive power in all the
cases we study.
Application to drug discovery
Finally, we demonstrate that our algorithm can be used to
discover interactions of novel drugs as part of the drug discovery
process. In particular, consider a lab that has developed a new
drug D which is known to have a harmful interaction with another
drug H1. Ideally, the lab wants to identify all other drugs
fH2,H3, . . .Hmg that also have harmful interactions with D. Since
in principle there are as many potential interactions as drugs in the
market (more than 1,000, according to the Drugbank and
Drugs.com databases), it would be extremely costly to test all
possible interactions experimentally. Considering that the typical
drug interacts with approximately 20–40 other drugs (in
Network Inference for Drug-Drug Interactions
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DrugBank and Drugs.com, respectively), random testing for
interactions would require 35–55 experiments to uncover a single
harmful interaction.
Lacking any knowledge about D (other than its interaction with
H1), our algorithm can guide experiments by identifying those
drugs that are most likely to interact with D. In particular, we
could use the stochastic block model inference approach to predict
the most likely interaction, test it in the lab, and iterate the process
adding, at each iteration, whatever interaction information the lab
assay gave.
To test whether such an approach would work in practice, we
have simulated the discovery of two drugs whose interactions are
in fact known and reported in the 2012 snapshot of DrugBank—
acetophenazine and cinacalcet (these drugs were selected
randomly among those with 10 to 20 interactions). For each of
these drugs, we proceed exactly as if no data were available in the
Figure 2. Performance of drug interaction inference methods on exhaustive pair interaction data. We test the algorithms against results
of two experiments in which all pairwise interactions between a small set of drugs were tested: [28] (A, C and E; interactions are synergistic, additive
or antagonistic) and [20] (B, D and F; interactions are synergistic, additive, antagonistic or suppressing). We simulate situations in which only a
fraction f of all interactions are observed, and then try to predict the unobserved interactions (repeated random sub-sampling validation). In each
case, we measure the fraction of predictions that are exactly correct (A and B), as well as the fraction of predictions that deviate from the
experimental observation by at most one level (C and D). For example, miss-predicting a synergistic interaction as additive is considered correct by
the +1 classification metric, but miss-predicting a synergistic interactions as antagonistic or suppressing (or vice versa), or an additive one as
suppressing (or vice versa) is considered incorrect. Error bars indicate the standard error of the mean and are usually smaller than the symbols. (E and
F) Relative improvement of the stochastic block model predictions over the neighbor-based predictions. If c is the frequency of correct classification,
we define the relative improvement as (cSBM{cX)=(cX{cB), where SBM and B stand for stochastic block model and baseline, respectively, and X
stands for any other approach (neighbor-based or Prism-based).
doi:10.1371/journal.pcbi.1003374.g002
Network Inference for Drug-Drug Interactions
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database except for one seed interaction H1, which we also
choose at random. From the seed interaction and interaction data
for all drugs other than D, we use the stochastic block model
approach to infer the next most likely interaction of D, check if
the interaction truly exist, add this information to the network,
and iterate.
As we show in Fig. 4, the results are very promising. For
acetophenazine, the 16 iterations we carry out are enough to
discover 11 of the 15 interactions that are reported in DrugBank.
For cinacalcet, we are able to uncover 8 of the 12 reported
interactions. As mentioned above, these numbers need to be
compared with the approximately 55 experiments that would be
necessary to uncover a single interaction without any guidance.
Discussion
There is a pressing need to elucidate and understand
interactions between drugs. With thousands of drugs in the
market, and hundreds or thousands being tested and developed, it
is clear that we cannot rely only on experimental assays to uncover
interactions. Therefore, we need to develop computational data-
mining methods to guide experimental analysis.
There are many possible approaches to predict drug interac-
tions computationally. One is to mine patient data that are
collected as part of post-marketing surveillance. However, this
Figure 3. Performance of drug interaction inference methods
on an evolving database of major adverse drug interactions.
Left: Drugs.com database; right: DrugBank dataset. (A–B) Area under
the receiver operating characteristic (AUROC) curve. For novel
interactions the AUROC gives the probability that an interaction
randomly chosen from those that were added to the first snapshot has
a higher score than one randomly chosen from the set of interactions
that were never added to the network. Similarly, for spurious
interactions the AUROC gives the probability that an interaction
randomly chosen from those that were removed from the first snapshot
has a lower score than one randomly chosen from the set of
interactions that were not removed from the network. (C–F)
Sensitivity-specificity curves for novel (C–D) and spurious interactions
(E–F). Sensitivity is defined as the ratio of true positives to all real
positives (true positives plus false negatives). Specificity is defined as
the ratio of true negatives to all real negatives (true negatives plus false
positives).
doi:10.1371/journal.pcbi.1003374.g003
Figure 4. Inference of drug interactions as part of the process of
drug discovery and development. For each of the two drugs ((A)
acetophenazine and (B) cinacalcet) we simulate an iterative process in
which a plausible interaction is suggested by the stochastic block model
inference approach, the interaction is tested, and information is added
to the network of known drug-drug interactions. The graphs display the
number of true interactions discovered as a function of the number of
experiments carried out. Green dots represent true interactions, whereas
red dots represent drugs that were suggested as interaction candidates
but turned out not to interact with the target drug. For acetophenazine,
the 16 iterations we carry out are enough to discover 11 of the 15
interactions that are reported in DrugBank. For cinacalcet, we are able to
uncover 8 of the 12 reported interactions. The gray region indicates the
feasible region of discovery. Its upper bound corresponds to discovering
all interactions without ever testing a drug that does not interact with
the target drug; the lower bound corresponds to randomly exploring all
possible interactions. In the lower bound, it takes around 100
experiments to uncover each interaction.
doi:10.1371/journal.pcbi.1003374.g004
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approach is problematic because of confounding factors that may
not be properly accounted for in existing reporting systems [32].
Another approach is to use models based on molecular and
pharmacological data [15].
Our approach is complementary to these efforts, and exploits
the information that is encoded in the network of known drug
interactions—since known interactions are the result of certain
(known or unknown) ‘‘pharmacological rules’’, we can infer
‘‘rules’’ from known interactions and then use the inferred ‘‘rules’’
to, in turn, predict unreported interactions (as we show in the
Supporting Text S1 and Fig. S2, the inferred ‘‘rules’’ correlate
strongly with drug structure, category and target). Although the
network approach has been frequently invoked as a new paradigm
in pharmacology [7,8] and there are large-scale databases that
compile and report drug interactions [10,30], this is, to the best of
our knowledge, the first attempt to use network inference to
predict drug interactions.
The network inference algorithm we have presented is very
abstract and does not take into consideration any information
other than reported interactions. It may be necessary in the future
to complement the method with chemical, biological and/or
pharmacological information. However, one advantage of our
abstract approach is that, precisely because it is abstract, it can be
easily extended to other kinds of pharmacological interaction data
that can be represented as networks. For example, it is
straightforward to extend our approach to predict associations
between drugs and adverse side effects from pharmacosafety networks
[33], protein- and target-drug interactions [34,35], or associations
between drugs and therapies [15] and drugs and diseases [36],
which may help to guide drug repositioning. Our approach can
even be used to predict gene-disease associations [37] and,
therefore, to uncover novel targets.
Another interesting extension of our approach is to predict
multidrug interactions (that is, interactions between groups of
three or more drugs), which are relevant to cancer treatment
among others. Although it seems that knowledge of pair
interactions may be enough to describe higher-order interactions
[16], within our framework tertiary interactions could also be
modeled using three-dimensional stochastic block models in which
the probability Q(sA,sB,sC) that three drugs A, B and C interact
depends only on the groups sA, sB and sC to which they belong.
The generalization to interactions between any number of drugs is
straightforward. All in all, we think that our approach opens the
door to new ways of looking at and making predictions from
pharmacological networks.
Methods
Dataset collection
For the Yeh et al. dataset, we collected the data on pairwise
combinations of 21 antibiotics from Figs. 3 and 4a of [20]. For the
Cokol et al. dataset, we collected the data on pairwise combinations
of 13 anti-fungal drugs from Fig. 3 of [28].
For the Drugs.com dataset, we collected all drug interactions
that were listed in the website, starting from a small set of highly
connected seed drugs. Drugs that are not connected, directly or
indirectly, to the seed drugs are not included in our analysis. We
limited our searches to ‘‘generic drugs’’ (which include common
combinations of generic drugs such as acetaminophen/hydroco-
done) and to ‘‘major interactions.’’ We consider two snapshots of
the database from May 10, 2010, and February 22, 2012.
Finally, for the DrugBank, we downloaded two snapshots of the
complete database, corresponding to January 2009 and April
2012, from http://www.drugbank.ca/downloads [29,30].
Estimation of link type probability using stochastic block
models
The fundamental assumption of our approach is that the
structure of the drug interaction network can be satisfactorily
accounted for by a model M, which is unknown but belongs to a
family M of models, that is, a group of models that can be
parametrized in some consistent way. Then, the probability that
rij~R given the observed network N
O is [19]
p(rij~RDNO)~
ð
M
dMp(rij~RDM)p(M DNO), ð1Þ
To estimate this integral we rewrite it, using Bayes theorem, as
[19,38]
p(rij~RDNO)~
Ð
M dMp(rij~RDM)p(N
ODM)p(M)Ð
M dMp(N
ODM)p(M)
: ð2Þ
Here, p(NODM) is the probability of the observed interactions
given a model and p(M) is the a priori probability of a model,
which we assume to be model-independent p(M)~const.
For the family of stochastic block models, each model
M~(P,Q1, . . . ,QK ) is completely determined by a partition P
of drugs into groups and the group-to-group interaction proba-
bility matricesQR. Here, K is the total number of interaction types
(for example, if interactions can be synergistic, additive or
antagonistic, then K~3) and, for a given partition P, the matrix
element QR(a,b) is the probability that a drug in group a and a
drug in group b interact with each other (these matrices verify thatP
r Q
r(a,b)~1 for all pairs of groups (a,b)). Thus, if i belongs to
group si and j to group sj we have that [38]
p(rij~RDM)~QR(si,sj) ; ð3Þ
and
p(NODM)~P
aƒb
P
r
Qr(a,b)n
r(a,b), ð4Þ
where nr(a,b) is the number of interactions of type r between drug
groups a and b.
The integral over all models in M can be separated into a sum
over all possible partitions of the drugs into groups, and an integral
over all possible values of each Qr(a,b). Using this together with
Eqs. (2), (3) and (4), and under the assumption of no prior
knowledge about the models (p(M)~const:), we have
p(rij~RjRO)~
1
Z
X
P
ð
S
dQ1 . . .
ð
S
dQK QR(si,sj)P
aƒb
P
r
Qr(a,b)n
r(a,b);
ð5Þ
where the integral is over all Qr(a,b) within the subspace S that
satisfies the normalization constraints
P
r Q
r(a,b)~1, and Z is the
normalizing constant (or partition function). These integrals
factorize into terms corresponding to all pairs (a,b) [38], each
with the general form
Network Inference for Drug-Drug Interactions
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ð1
0
dQ1(Q1)n
1
ð1{Q1
0
dQ2(Q2)n
2   
ð1{Q1{...{QK{2
0
dQK{1(QK{1)n
K{1
(1{Q1{ . . .{QK{1)n
K
~
n1!n2! . . . nK !
(n1zn2z . . .znKzK{1)!
:
Using these expressions in Eq. (5), one obtains
p(rij~RDNO)~
1
Z
X
P
nR(si,sj)z1
n(si,sj)zK
 
exp({H(P)), ð6Þ
where the sum is over all partitions of the drugs,
n(si,sj)~
P
r n
r(si,sj) is the total number of known interactions
between groups si and sj , and H(P) is a function that depends on
the partition only
H(P)~
X
aƒb
ln(n(a,b)zK{1)!{
XK
r~1
ln nr(a,b)ð Þ!
" #
: ð7Þ
This sum can be estimated using the Metropolis algorithm [19,39]
as detailed next.
Implementation details
The sum in Eq. (6) cannot be computed exactly because the
number of possible partitions is combinatorially large, but can be
estimated using the Metropolis algorithm [19,39]. This amounts to
generating a sequence of partitions in the following way. From the
current partition P0, select a random drug and move it to a
random new group giving a new partition P1. If H(P1)vH(P0),
always accept the move; otherwise, accept the move only with
probability eH(P
0){H(P1).
By doing this, one gets a sequence of partitions fPig such that
[39]
p(rij~RDNO)&
1
N
X
P[fPig
nR(si,sj)z1
n(si,sj)zK
, ð8Þ
where N is the number of samples in fPig.
In practice, it is useful to ‘‘thin’’ the sample fPig, that is, to
consider only a small fraction of evenly spaced partitions so as to
avoid the computational cost of sampling very similar partitions
which provide very little additional information. Moreover, one
needs to make sure that sampling starts only when the sampler is
‘‘thermalized’’, that is, when sampled partitions are drawn from
the desired probability distribution (which in our case is given by
e{H(P)=Z). Our implementation automatically determines a
reasonable thinning of the sample, and only starts sampling when
certain thermalization conditions are met. Therefore, the whole
process is completely unsupervised. The source code of our imple-
mentation of the algorithm is publicly available from http://
seeslab.info/downloads/drugraph/ and http://github.com/seeslab/
drugraph.
As often happens in Metropolis sampling, in general it is better
to run many short independent sampling processes that a single
very long sampler. Results reported here are obtained using 50
independent sampling processes of 200 (conveniently thinned)
partitions each. These sampling processes can be run in parallel,
taking on the order of 1–2 days to complete on high-end CPUs for
the largest network considered here (with over 1,500 drugs).
Sampling an equivalent 10,000 partitions with a single run can
take 2–3 weeks.
Prism-based prediction of interactions
The Prism algorithm [27] was originally developed to identify
groups of genes that interact monochromatically, that is, that have
the same type of interactions with genes in other groups. Yeh and
coworkers then introduced Prism II [20] to identify groups of
drugs relaxing the requirement for perfect monochromaticity.
Our implementation of Prism II is as follows. Each drug is
initially placed in a group by itself. Then, groups are sequentially
merged until all drugs belong to a single group. At each step, we
merge the two groups with the smallest ‘‘distance’’ to each other.
The distance Fab between groups a and b is
Fab~ min
i[a,j[b
fdijg{TDSab: ð9Þ
Here, the normalized drug-drug distance dij between drugs i and j
is
dij~
1
K{1
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiP
k rik{rjk
 2
Nij
s
, ð10Þ
with Nij the number of interactions reported for both i and j. The
change of monochromaticity entropy DSab is
DSab~S(mabzmaazmbb)
{S(mab){S(maa){S(mbb)
z
X
s=ab
S(maszmbs){S(mas){S(mbs)
  ð11Þ
where mab~(m
{
ab,m
z
ab) is a vector with the number of synergistic
(2) and antagonistic (+) interactions between groups a and b, and
S(m)~
mzzm{
MzzM{
(pz log pzzp{ log p{) ð12Þ
with pz={~mz={=(mzzm{) and Mz={~
P
abm
z={
ab :
By itself, the Prism II algorithm returns a tree of nested drug
groupings. To make interaction predictions, we need to: (i) set the
free parameter T ; (ii) cut the tree at a certain level to get a single
partition of the drugs into groups (a process that needs to be
unsupervised); and (iii) given those groups, determine the
probability of each type of interaction. To cut the tree, we choose
the partition with the smallest number of groups among those with
total monochromaticity entropy S~
P
a,b S(mab) that satisfies
Sv0:10Smax, where Smax is the partition that corresponds to
putting all drugs in a single group. Additionally, we set T~10 to
get results consistent with those reported in Ref. [20] (we also
checked that these parameters yield good results for the Cokol
dataset, and that the results do not improve using other values of
T ; see Supporting Text S1 and Fig. S1).
Finally, once the groups are defined, we estimate the probability
pPrism(rij~RDNO) as
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pPrism(rij~RDNO)~
nR(si,sj)
n(si,sj)
, ð13Þ
where nR(si,sj) and n(si,sj) are defined as above.
With our implementation, the Prism-based algorithm takes 1–2
days on high-end CPUs to generate interaction predictions for the
large networks considered here (with over 1,000 drugs).
Neighbor-based prediction of interactions
Given a network of drug interactions, we define the interaction
similarity sik between drugs i and k as the fraction of interactions
with other drugs that are equal for i and k, over the total number
of interactions that are reported for both drugs. In particular
sii~1, and sik~0 if two drugs do not have any equal interaction
with others.
To predict the interaction rij between drugs i and j, we order all
possible drug pairs (ki,kj) by decreasing value of the product of
similarities to the query drugs siki|sjkj . We then select the pair
(ki~i’,kj~j’) with the highest product for which the interaction
ri’j’ is known, and use that value as our prediction of rij . Note that
we may have i’~i, that is, we may use the known interaction
between i and a drug j’ that is very similar to j to predict rij .
Supporting Information
Figure S1 The accuracy of the Prism-based method, as
measured by the AUROC, does not improve consistently and
significantly by choosing values of T other than T~10, as used in
the main text.
(TIFF)
Figure S2 Drug groups and drug mechanisms of action from
stochastic block models. For each drug pair in the Cokol et al.
dataset (A–B), the Yeh et al. dataset (C–D) and the DrugBank 2012
snapshot (E), we calculate the probability that any two drugs
belong to the same drug group (see Section 2). We call this
probability the co-classification probability. (A) and (C) The matrix
of co-classification probabilities for the Cokol et al. dataset (A), and
Yeh et al. dataset (C), ordered so that large co-classification
probabilities appear close to the diagonal [40]. Dashed lines are a
guide to the eye. The mechanism of action of each drug is
indicated by color bars on top of drug abbreviations ((A) Cyan:
ergosterol metabolism; dark red: acting on serine/threonine; other
drugs were intentionally selected with different targets and
mechanisms of action. (C) Dark red: protein synthesis, 30S; cyan:
protein synthesis, 50S; red: folic acid biosynthesis; pink: DNA
gyrase; dark blue: cell wall; yellow: aminoglycoside, protein
synthesis, 30S). Co-classification boxes correspond, to a large
extent, to mechanisms of action. (B) and (D) The reported drug
interactions show clear patterns once they are ordered according
to the co-classification probability. For example in the Yeh et al.
dataset, most interactions between the group fAMK,STR,TOBg
and the group fTMP,SLF,NIT,CPR,LOMg are synergistic. (E)
We use information in DrugBank to analyze the overlap (or
functional similarity) in substructure, category and target between
pairs of drugs (see Section 3). We plot these quantities as a function
of the co-classification probability of the corresponding drug pairs
(we average over drug pairs with similar co-classification
probability; error bars represent the standard error of the mean
and are generally smaller than the symbols). Drugs with higher co-
classification probability are significantly more likely to share
substructures, categories and targets.
(TIFF)
Text S1 Sensitivity analysis for the Prism-based algorithm.
Discussion on drug groups and drug mechanisms. Discussion on
the estimation of the co-classification probability using stochastic
block models. Analysis of drug similarities for drugs in the
DrugBank.
(PDF)
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